Cure My Disease

Don't miss your cure!

 Log in / Sign up

New nerve block aims to stop chronic pain after mastectomy

NCT ID NCT07289178

Not yet recruiting Symptom relief Sponsor: First Affiliated Hospital of Kunming Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single injection of liposome bupivacaine, a long-acting anesthetic, into the chest wall can reduce pain sensitivity and prevent chronic pain after radical mastectomy. 120 breast cancer patients will receive the nerve block during surgery, and their pain thresholds and pain scores will be tracked for 6 months. The goal is to see if this approach can improve recovery and lower the risk of lasting pain.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
liposome bupivacaine
What this could lead to
If it works, this could provide a way to reduce long-term pain after mastectomy, improving recovery and quality of life for breast cancer patients.
What could go wrong
This is an early-phase study with only 120 participants, so results may not apply to everyone. The nerve block may not significantly reduce chronic pain, and there are risks like allergic reaction or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC POST-SURGICAL PAIN LIPOSOMAL BUPIVACAINE POSTOPERATIVE HYPERALGESIA RADICAL MASTECTOMY SURGERY SERRATUS PLANE BLOCK

Contacts and locations

Locations

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.